| |
| Device | PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody |
| Generic Name | SYSTEM, TEST, HER-2/NEU, IHC |
| Applicant | Ventana Medical Systems, Inc. 1910 E. Innovation Park Dr. Tucson, AZ 85755 |
| PMA Number | P990081 |
| Supplement Number | S047 |
| Date Received | 05/27/2022 |
| Decision Date | 09/30/2022 |
| Product Code |
MVC |
| Docket Number | 22M-2439 |
| Notice Date | 10/07/2022 |
| Advisory Committee |
Pathology |
| Clinical Trials | NCT03734029
|
| Supplement Type | Panel Track |
| Supplement Reason | Labeling Change - Indications/instructions/shelf life/tradename |
| Expedited Review Granted? | No |
| Combination Product | No |
| Predetermined Change Control Plan Authorized | No |
Approval Order Statement Approval for the PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody for expanding the indications to include testing for breast cancer patients who are eligible for treatment with ENHERTU®. |
| Approval Order | Approval Order |
| Summary | Summary of Safety and Effectiveness |
| Labeling | Labeling Labeling Part 2 |